This bill directs the Secretary of Labor, through OSHA, to produce two things within 270 days of enactment: nonmandatory guidance for employers about acquiring and maintaining opioid overdose reversal medication and voluntary annual employee training on its use; and mandatory regulations requiring every Federal agency to acquire and maintain such medication and offer that same annual voluntary training. The statutory employer definition borrows from the OSH Act but expressly excludes the United States Postal Service, while the definition of Federal agency explicitly includes the Veterans Health Administration.
For compliance officers and agency procurement leads, the bill creates a short regulatory clock and a bifurcated approach: private-sector employers receive guidance (advice, not a legal mandate), while federal agencies get a binding regulatory duty. The measure leaves enforcement tools and funding to implementing regulations, so operational details—stocking levels, storage, training standards, and liability protections—will be resolved by OSHA rulemaking rather than the statute itself.
At a Glance
What It Does
The bill requires OSHA to issue nonbinding workplace guidance to employers on acquiring and maintaining opioid overdose reversal medication and providing annual voluntary training. Separately, OSHA must issue binding regulations that compel every Federal agency to keep such medication on site and offer annual voluntary training to employees.
Who It Affects
Federal agencies and their procurement and occupational safety offices face a new regulatory duty; private employers receive guidance (they are not legally required but may follow recommendations). OSHA and agency HR and emergency-response teams will need to translate guidance into procurement, storage, and training operations.
Why It Matters
It establishes a federal administrative baseline for workplace access to naloxone and training that could shape private-sector practices without directly imposing new statutory obligations on employers. For federal workplaces, the bill creates an affirmative compliance obligation that agencies must fold into safety programs and budgets.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The statute is short and focused. It sets two parallel tracks for dealing with opioid overdose reversal medication (commonly naloxone): nonmandatory guidance for employers generally, and mandatory regulations for all Federal agencies.
Both tracks address two discrete actions—acquiring and maintaining the medication, and providing annual voluntary training to employees on how to use it—but the legal force differs by track.
For private employers, OSHA must publish nonbinding guidance within 270 days explaining how to obtain and keep on hand overdose reversal medication and how to run voluntary annual training programs. Because the guidance is nonmandatory, private employers will not automatically face penalties for failing to follow it; the guidance is intended to inform best practices, leaving adoption decisions to individual employers who will weigh costs, workplace risk profile, and legal exposure.For the federal government, OSHA must convert similar concepts into binding regulations within the same 270-day deadline.
The bill defines 'Federal agency' broadly to include agencies and instrumentalities and explicitly names the Veterans Health Administration, sidestepping 38 U.S.C. 7425(b) as a potential exemption. Those regulations will require agencies to procure and maintain overdose reversal medication and to offer annual voluntary training—meaning agencies must add procurement, inventory, and training functions into existing occupational-safety programs.The statute is deliberately silent on specifics such as minimum kit counts per facility, storage and disposal standards, who may administratively authorize kits, recordkeeping, or civil liability protections for rescuers.
Those operational decisions are left to OSHA's guidance and subsequent regulatory rulemaking, so the real-world effect will pivot on the detail and enforceability of the implementing documents.
The Five Things You Need to Know
OSHA has 270 days after enactment to issue nonmandatory guidance to employers on acquiring and maintaining opioid overdose reversal medication and offering voluntary annual training.
The bill requires OSHA, also within 270 days, to issue binding regulations that force every Federal agency to acquire and maintain overdose reversal medication and offer annual voluntary employee training.
The statutory definition of 'employer' tracks the OSH Act definition but expressly excludes the United States Postal Service from the employer-targeted guidance.
The bill defines 'Federal agency' to include agencies and instrumentalities of the Federal Government and explicitly includes the Veterans Health Administration despite 38 U.S.C. 7425(b).
The statute sets duties (acquire/maintain medication; offer voluntary annual training) but does not prescribe quantities, storage standards, funding, enforcement mechanisms, or liability protections—those are reserved for OSHA's implementing guidance and regulations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the Act as the "Workplace Overdose Reversal Kits to Save Lives Act" (WORK to Save Lives Act). This is purely nominal but signals the statute's dual focus on workplace kits and life-saving training.
Nonmandatory employer guidance (OSHA)
Directs the Secretary of Labor, through OSHA, to publish nonbinding guidance within 270 days advising employers on two topics: how to acquire and maintain opioid overdose reversal medication and how to offer voluntary annual training to employees on its use. The section borrows the OSH Act's definition of 'employer' but carves out the United States Postal Service. Practically, this gives OSHA latitude to set best practices without imposing statutory penalties on private employers, which will influence compliance only to the extent employers choose to follow the guidance or incorporate it into their safety programs.
Mandatory federal-agency regulations (OSHA)
Requires OSHA to issue binding regulations within 270 days that compel every Federal agency to both acquire/maintain overdose reversal medication and offer voluntary annual training to employees on its use. The section defines 'Federal agency' broadly and expressly includes the Veterans Health Administration, removing a potential statutory exemption under 38 U.S.C. 7425(b). Because the statute delegates the implementation details to OSHA, agencies will be accountable under the forthcoming regulations for procurement cycles, inventory management, training delivery, and compliance monitoring once OSHA issues them.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal employees — Agencies will be required to keep naloxone on site and offer annual training, increasing the likelihood of a timely workplace overdose response.
- Employees at private workplaces that choose to follow OSHA's guidance — Voluntary adoption of guidance can reduce overdose fatalities and create safer workplaces without new statutory mandates.
- Occupational safety and health professionals — The bill creates a clear entry point to integrate overdose response into existing emergency preparedness programs and training portfolios.
Who Bears the Cost
- Federal agencies — Must budget for purchase, storage, replacement (including expired product), and staff time for training and program administration under binding regulations.
- Private employers who adopt the guidance — Although nonmandatory, employers that implement recommendations will face procurement, training, and recordkeeping costs.
- OSHA and agency compliance units — OSHA must draft guidance and regulations on a 270-day clock, and agencies must operationalize and enforce the new regulatory duties, creating administrative burdens that may require additional staffing or reallocation of resources.
Key Issues
The Core Tension
The central dilemma is straightforward: the bill advances an urgent public-health goal—making overdose reversal medication and training more available at work—while avoiding direct mandates on private employers, which preserves employer discretion but risks uneven adoption; at the same time it places binding obligations on federal agencies without providing dedicated funding or operational detail, forcing agencies to choose between rapid implementation, fiscal trade-offs, or delayed rollout.
The bill establishes policy direction but defers almost every operational detail to OSHA's implementing documents. That delegation creates implementation risk: without statutory minimums for kit quantities, storage, authorized administrators, or training curricula, agencies and employers may adopt widely divergent practices that produce inconsistent protection across workplaces.
The absence of funding language means agencies must absorb costs into existing budgets unless separate appropriations follow, which could slow or limit rollout, particularly at smaller facilities or field offices.
Legal and logistical tensions are unresolved. The statute does not address civil liability for administrators of naloxone in the workplace, interaction with state Good Samaritan and standing order frameworks for naloxone access, or how agencies should handle controlled-substance or prescription-related procurement mechanics.
Supply-chain factors—product availability, expiration management, and disposal—are real-world constraints that could undermine stocking expectations. Finally, because the employer guidance is nonmandatory, private-sector uptake will depend on perceived legal risk and cost-benefit calculations rather than a uniform regulatory floor.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.